Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis

US11351185B2 · kind B2 · utility

Assignees

• ASCLEA CORPORATION · US
• THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · US

Inventors

• Enhong JIANG · 东风镇, CN
• Zhengping Zhuang · Bethesda, US
• Jing Cui · Nanhu, CN

Key dates

• Filing date: Mar 11, 2020
• Grant date: Jun 7, 2022
• Expiry date: Mar 11, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A pharmaceutical composition containing any one or more of 4″-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to trigger genomic instability and cell-cycle arrest in cancer cells.